Conferences
Conference Details
The FDA approved only 22 new drug candidates in 2016 � less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its lowest level since 2009. In the face of this regulatory and financial uncertainty, biotech companies must increasingly rely on creative deal-making and the discovery of new indications for established products.
Date :
Place : United States, Boston
Contact Person:Paula Edwards
Description:
The FDA approved only 22 new drug candidates in 2016 — less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its lowest level since 2009. In the face of this regulatory and financial uncertainty, biotech companies must increasingly rely on creative deal-making and the discovery of new indications for established products.The FDA approved only 22 new drug candidates in 2016 � less than half of the prior year, and the lowest level since 2010. The IPO market has collapsed to its lowest level since 2009. In the face of this regulatory and financial uncertainty, biotech companies must increasingly rely on creative deal-making and the discovery of new indications for established products. will be held in Boston,United States on date 2017-09-27
Deadline for abstracts/proposals : 8th September 2017
Organized By :New York Events List
Keynote Speakers :
Conference Highlights :Key subject areas Mergers & acquisitions to strengthen your drug pipeline Remote clinical monitoring and its impact on development speed The art of the biotech deal: creating syndicates and driving value Building relationships and networking with KOLs
Venue :Boston, MA 02210, United States
Check the event website for more details.
Views:
743